Impact of modulation of the α7 nicotinic acetylcholine receptor on nicotine reward in the mouse conditioned place preference test
The α7 nicotinic acetylcholine receptor (nAChR) has been implicated as a target in modulating nicotine reward. However, the effect of pharmacological agents that have been shown to alter the channel properties of the α7 nAChR is not well understood in nicotine reward.
This study aimed to investigate the impact of α7 nAChR pharmacological modulation on nicotine conditioned place preference (CPP) in mice by using positive allosteric modulators (PAMs) and a silent agonist.
The effect of the orthosteric α7 nAChR full agonist PNU282987 (1.3 and 9 mg/kg, s.c.), Type I α7 PAM NS1738 (1 and 10 mg/kg; i.p.), the Type II α7 PAM PNU120596 (0.3, 1, and 3 mg/kg, i.p.), and the α7 silent agonist NS6740 (1 and 3 mg/kg, i.p) on nicotine CPP was measured in mice. Mice were conditioned with either saline or nicotine (0.5 mg/kg) for 3 days in the CPP paradigm.
The α7 full orthosteric agonist PNU282987 and the Type II α7 nAChR PAM PNU120596 reduced nicotine CPP, while the silent agonist NS6740 and Type I PAM NS1738 had no effect. The effects of PNU282987 and PNU120596 did not have an effect on morphine CPP.
Taken together, our results suggest that modulation of the α7 nAChR can play important roles in nicotine CPP in mice. In addition, the Type II α7 nAChR PAM PNU120596 attenuated nicotine reward suggesting that endogenous acetylcholine/choline tone is sufficient to reduce nicotine CPP. These findings highlight a beneficial effect of using α7 nAChR PAMs in nicotine reward.
KeywordsNicotine Mice Conditioned place preference Reward
This study was supported by NIH grant [DA 005274 and DA032246] to MID. AJ was supported by T32 (DA007027) from NIH. RLP was supported by [GM57481].
Compliance with ethical standards
Experiments were performed during the light cycle and were approved by the Institutional Animal Care and Use Committee of Virginia Commonwealth University and followed the National Institutes of Health Guidelines for the Care and Use of Laboratory Animals.
Conflict of interest
The authors declare that they have no conflict of interest.
- Briggs CA, Grønlien JH, Curzon P, Timmermann DB, Ween H, Thorin-Hagene K, Kerr P, Anderson DJ, Malysz J, Dyhring T, Olsen GM, Peters D, Bunnelle WH, Gopalakrishnan M (2009) Role of channel activation in cognitive enhancement mediated by Alpha7 nicotinic acetylcholine receptors. Br J Pharmacol 158:1486–1494. https://doi.org/10.1111/j.1476-5381.2009.00426.x CrossRefGoogle Scholar
- Freitas K, Negus S, Carroll FI, Damaj MI (2013c) In vivo pharmacological interactions between a type II positive allosteric modulator of α7 nicotinic ACh receptors and nicotinic agonists in a murine tonic pain model. Br J Pharmacol 169:567–579. https://doi.org/10.1111/j.1476-5381.2012.02226.x CrossRefGoogle Scholar
- Gee, K.W., Olincy, A., Kanner, R., Johnson, L., Hogenkamp, D., Harris, J., Tran, M., Edmonds, S.A., Sauer, W., Yoshimura, R., Johnstone, T., Freedman, R., 2017. First in human trial of a type I positive allosteric modulator of alpha7-nicotinic acetylcholine receptors: pharmacokinetics, safety, and evidence for neurocognitive effect of AVL-3288 1–8. doi: https://doi.org/10.1177/0269881117691590
- Grottick AJ, Trube G, Corrigall WA, Huwyler J, Malherbe P, Wyler R, Higgins GA (2000) Evidence that nicotinic α7 receptors are not involved in the hyperlocomotor and rewarding effects of nicotine. J. Pharmacol. Exp. Ther. 294, 1112–1119.Google Scholar
- Hopkins TJ, Rupprecht LE, Hayes MR, Blendy JA, Schmidt HD (2012) Galantamine, an acetylcholinesterase inhibitor and positive allosteric modulator of nicotinic acetylcholine receptors, attenuates nicotine taking and seeking in rats. Neuropsychopharmacology 37:2310–2321. https://doi.org/10.1038/npp.2012.83 CrossRefGoogle Scholar
- Jackson, A., Bagdas, D., Muldoon, P.P., Lichtman, A.H., Carroll, F.I., Greenwald, M., Miles, M.F., Damaj, M.I., 2017. In vivo interactions between α7 nicotinic acetylcholine receptor and nuclear peroxisome proliferator-activated receptor-α: implication for nicotine dependence. Neuropharmacology 118. doi: https://doi.org/10.1016/j.neuropharm.2017.03.005
- Livingstone PD, Srinivasan J, Kew JNC, Dawson LA, Gotti C, Moretti M, Shoaib M, Wonnacott S (2009) alpha7 and non-alpha7 nicotinic acetylcholine receptors modulate dopamine release in vitro and in vivo in the rat prefrontal cortex. Eur J Neurosci 29:539–550. https://doi.org/10.1111/j.1460-9568.2009.06613.x CrossRefGoogle Scholar
- Kowal NM, Ahring PK, Liao VWY, Indurti DC, Harvey BS, O'Connor SM, Chebib M, Olafsdottir ES, Balle T, (2017) Galantamine is not a positive allosteric modulator of human α4β2 or α7 nicotinic acetylcholine receptors. British Journal of Pharmacology 175 (14):2911–2925.Google Scholar
- Papke RL, Bagdas D, Kulkarni AR, Gould T, Alsharari SD, Thakur GA, Damaj MI (2015) The analgesic-like properties of the alpha7 nAChR silent agonist NS6740 is associated with non-conducting conformations of the receptor. Neuropharmacology 0:34–42. https://doi.org/10.1016/j.neuropharm.2014.12.002 CrossRefGoogle Scholar
- Papke R, Stokes C, Damaj M, Thakur G, Manther K, Treinin M, Bagdas D, Kulkarni AR, Horenstein NA (2017) Persistent activation of α 7 nicotinic ACh receptors associated with stable induction of different desensitized states. Br J Pharmacol 1–17:1838–1854. https://doi.org/10.1111/bph.13851 Google Scholar
- Papke RL, Peng C, Kumar A, Stokes C (2018) NS6740, an α7 nicotinic acetylcholine receptor silent agonist, disrupts hippocampal synaptic plasticity. Neurosci Lett 677:6–13. https://doi.org/10.1586/14737175.2015.1028369.Focused CrossRefGoogle Scholar
- Perkins KA, Roy Chengappa KN, Karelitz JL, Boldry MC, Michael V, Herb T, Gannon J, Brar J, Ford L, Rassnick S, Brunzell DH (2018) Initial cross-over test of a positive allosteric modulator of Alpha-7 nicotinic receptors to aid cessation in smokers with or without schizophrenia. Neuropsychopharmacology 43:1334–1342. https://doi.org/10.1038/npp.2017.292 CrossRefGoogle Scholar
- Pieschl RL, Miller R, Jones KM, Post-Munson DJ, Chen P, Newberry K, Benitex Y, Molski T, Morgan D, McDonald IM, Macor JE, Olson RE, Asaka Y, Digavalli S, Easton A, Herrington J, Westphal RS, Lodge NJ, Zaczek R, Bristow LJ, Li YW (2017) Effects of BMS-902483, an α7 nicotinic acetylcholine receptor partial agonist, on cognition and sensory gating in relation to receptor occupancy in rodents. Eur J Pharmacol 807:1–11. https://doi.org/10.1016/j.ejphar.2017.04.024 CrossRefGoogle Scholar
- Schilström B, Nomikos GG, Nisell M, Hertel P, Svensson TH (1998) N-methyl-D-aspartate receptor antagonism in the ventral tegmental area diminishes the systemic nicotine-induced dopamine release in the nucleus accumbens. Neuroscience 82:781–789. https://doi.org/10.1016/S0306-4522(97)00243-1 CrossRefGoogle Scholar
- Timmermann DB, Grønlien JH, Kohlhaas KL, Nielsen EØ, Dam E, Jørgensen TD, Ahring PK, Peters D, Holst D, Chrsitensen JK, Malysz J, Briggs CA, Gopalakrishnan M, Olsen GM (2007) An allosteric modulator of the α7 nicotinic acetylcholine receptor possessing cognition-enhancing properties in vivo. J Pharmacol Exp Ther 323:294–307. https://doi.org/10.1124/jpet.107.120436.vidual CrossRefGoogle Scholar
- Winterer G, Gallinat J, Brinkmeyer J, Musso F, Kornhuber J, Thuerauf N, Rujescu D, Favis R, Sun Y, Franc MA, Ouwerkerk-Mahadevan S, Janssens L, Timmers M, Streffer JR (2013) Allosteric alpha-7 nicotinic receptor modulation and P50 sensory gating in schizophrenia: a proof-of-mechanism study. Neuropharmacology 64:197–204. https://doi.org/10.1016/j.neuropharm.2012.06.040 CrossRefGoogle Scholar